Daniela Cariranha Setúbal

Learn More
Allogeneic haematopoietic cell transplantation (HCT) is effective therapy for Fanconi anaemia (FA). FA patients do not tolerate conditioning with 200 mg/kg of cyclophosphamide (Cy), typically used in aplastic anaemia. We previously published results of studies in which Cy doses were gradually reduced from 200 to 100 mg/kg. Here we update results of the(More)
Umbilical cord blood has become a valuable alternative source of haematopoietic stem cells for allogeneic transplantation. However, largely because of the impact of cell dose on engraftment, risk of transplant-related mortality and survival, progress in the field has been largely restricted to children. Nevertheless, substantial clinical experience with(More)
Basiliximab is a chimeric monoclonal antibody that binds to the α chain of IL-2R on activated cytotoxic T-cells, inhibiting lymphocyte proliferation. We report 34 patients with refractory acute GVHD (grade III–IV) who received basiliximab from December 1998 to October 2003. Adults received 40 mg weekly (2–3 doses) and children received half of this dose.(More)
Cells from Fanconi anemia (FA) patients are hypersensitive to alkylating agents and radiation traditionally used as conditioning regimens for marrow cell transplantation, and patients experience serious toxicities. To reduce toxicities, we used progressively lower doses of cyclophosphamide (CY) for conditioning. Here, we report the results in 43 FA patients(More)
Juliane Morando1 Marcos Augusto Mauad2 Sérgio Costa Fortier1 Flavia Zattar Piazera1 Mair Pedro de Souza2 Claudia Oliveira2 Clarisse Machado2 Ederson Matos2 Wellington Moraes Azevedo2 Lisandro Lima Ribeiro1 Elenaide Coutinho Nunes1 Marco Antonio Bitencourt1 Daniela Cariranha Setúbal1 Vaneuza Moreira Funke1 Michel Michels de Oliveira1 Larissa Alessandra(More)
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been recently proposed to predict the probability of nonrelapse mortality (NRM) and overall survival (OS) in allogeneic HCT recipients while taking into account any pretransplant comorbidity. We tested the validity of the HCT-CI in a cohort of 373 adult HCT recipients (184(More)
Imatinib mesylate (IM) is now first-line treatment for CML. To study the results of treatment with IM after IFN failure/intolerance versus allogeneic BMT (allo-BMT), we retrospectively analyzed 264 patients treated for CML in first chronic phase in three different institutions. Over a 6-year period (2001–2006), 174 patients received IM after failure of or(More)
We transplanted 47 patients with Fanconi anemia using an alternative source of hematopoietic cells. The patients were assigned to the following groups: group 1, unrelated bone marrow (N = 15); group 2, unrelated cord blood (N = 17), and group 3, related non-sibling bone marrow (N = 15). Twenty-four patients (51%) had complete engraftment, which was not(More)
Correspondence to: Vaneuza A. M. Funke Rua da Paz, 412, apt 151 – Centro 80060-160 – Curitiba-PR – Brazil Tel.: 055 41 3601000 – Fax: 055 41 3601015 E-mail: vaneuza@brturbo.com.br Chronic Myeloid Leukemia (CML) is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 (Philadelphia chromosome). The resulting BCR-ABL gene has(More)
Bone marrow transplantation (BMT) is a therapeutic option for patients with genetic storage diseases. Between 1979 and 2002, eight patients, four females and four males (1 to 13 years old) were submitted to this procedure in our center. Six patients had mucopolysaccharidosis (MPS I in 3; MPS III in one and MPS VI in 2), one had adrenoleukodystrophy (ALD)(More)